Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal cancer with peritoneal carcinomatosis

Clinical outcomes at 2 tertiary referral centers in Korea

Eun Jung Park, MD, Seung Hyuk Baik, MD, PhD, Hyuk Hur, MD, Byung Soh Min, MD, PhD, Jeonghyun Kang, MD, Yun Dae Han, MD, Min Soo Cho, MD, Kang Young Lee, MD, PhD, Nam Kyu Kim, MD, PhD*

1. Introduction

Peritoneal carcinomatosis is the second most common metastatic lesion in patients with stage IV colorectal cancer, with a cancer recurrence incidence of 10% to 35%.1-2 When free intraperitoneal cancer cells are exfoliated from a primary cancer, they can be disseminated and lead to peritoneal metastasis or local recurrence.3 Meanwhile, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is based on the concept that microscopic residual tumors can be eradicated by direct penetration of anticancer drugs into tumor cells at 42°C to 43°C after removal of the macroscopic tumor.4 According to the randomized controlled trial by Verwaal et al,5,6 the median survival after CRS with HIPEC in patients with peritoneal metastasis of colorectal origin was improved above that achieved with standard systemic chemotherapy (22.3 vs 12.6 months, \( P = .032 \)).7 In a phase II multicentric French study, Elias et al7 reported that patients who underwent surgery with perioperative intraperitoneal chemotherapy experienced a median survival of 30.1 months with 27% of 3-year overall survival rates. Although CRS with HIPEC offers advantages in treating peritoneal metastasis, the procedure is technically demanding and must be performed by a highly experienced surgical team. Moreover, a high rate of postoperative complications and a steep learning curve hinder wider performance of CRS with HIPEC.8-12 Since July 2014, our institutions began offering CRS with HIPEC for patients with colorectal cancer with...
peritoneal carcinomatosis. In this study, we aimed to evaluate clinical outcomes of CRS with HIPEC and its feasibility in treating Korean patients with appendiceal or colorectal cancer with peritoneal carcinomatosis.

2. Methods

2.1. Study population and data collection

A colorectal surgeon (SH Baik) started CRC with HIPEC at Severance Hospital in July 2014, and since then, a total of 66 patients with peritoneal metastasis originating from colorectal or appendiceal cancer have undergone CRS with HIPEC at 2 tertiary referral hospitals (Severance Hospital and Gangnam Severance Hospital) of the Yonsei University Health System as of March 2016. Patients were diagnosed with peritoneal metastases preoperatively via abdomino-pelvic computed tomography (CT), positron emission tomography-CT, or diagnostic laparoscopy. Among patients diagnosed with peritoneal carcinomatosis, patients younger than 80 years with an Eastern Cooperative Oncologic Group (ECOG) score less than 2 were included in this study. Patients who had co-morbidities, with 34.8% of the patients having an ASA score of 3. The most frequent site of primary tumor was the ascending colon. Before CRS with HIPEC, 24 patients (36.4%) had a primary tumor with synchronous peritoneal metastasis, whereas 42 patients (63.6%) had metachronous peritoneal metastasis. In total, 50 patients had previously undergone abdominal surgeries. Among them, 42 patients underwent colorectal cancer surgery, and 3 patients had palliative surgery before CRS plus HIPEC. All 3 cases of palliative surgery were ileostomy formations to treat intestinal obstruction from peritoneal carcinomatosis.

2.2. Evaluation parameters

Preoperatively, patients were evaluated for combined morbidities and the American Society of Anesthesiologists (ASA) classification, along with assessment of previous chemotherapy history or abdominal surgery. Peritoneal Surface Disease Severity Score (PSDSS) was determined from stages I to IV, which were assessed according to 3 categories based on clinical symptoms, extent of carcinomatosis (peritoneal cancer index [PCI] on preoperative CT scan or first exploration), and histopathology of the primary tumor.[13,14]

PCI was assessed through the 13 abdomino-pelvic regions. Each region was graded using the following scale: 0 points, absence of tumor; 1 point, tumor less than 0.5 cm; 2 points, tumor from 0.5 cm to 5 cm; and 3 points, tumor larger than 5 cm. Completeness of cytoreduction (CC) was assessed according to the extent of the remnant tumor: CC-0, complete removal of visible tumor; CC-1, remnant tumor less than 0.25 cm; CC-2, residual tumor between 0.25 cm and 2.5 cm; and CC-3, visible tumor larger than 2.5 cm in diameter.

Synchronous operations were performed with resection of the primary tumor followed by a peritonectomy. The length of stay in the intensive care unit (ICU) was assessed from the day of the operation to admittance in the general ward. The length of hospital stay was calculated from the date of admission to discharge. Patients received adjuvant chemotherapy based on the regimens of FOLFOX, FOLFIRI, or capecitabine with targeted cancer therapeutics, such as bevacizumab or cetuximab. The interval of the first postoperative chemotherapy was calculated as the time elapsed from the date of the operation to the date the patient received the first cycle. Readmission was evaluated for complication-related admission after discharge.

Postoperative complications were classified by the Clavien–Dindo classification of surgical complications.[15,16] Short-term complications were considered as those that developed within the first 30 postoperative days, while long-term complications were evaluated when more than 30 days had elapsed.

2.3. Surgical technique

Before CRS, bowel preparation was performed, except in patients who had intestinal obstructions. Prophylactic antibiotics with a third-generation cephalosporin were administered. CRS was performed by resection of the metastatic organs from the primary cancer with a peritonectomy. Parietal peritonectomy and visceral resections were performed by following the Sugabaker techniques.[17,18] Anterior peritonectomy, upper quadrant peritonectomy, pelvic peritonectomy, subphrenic peritonectomy, and omental bursectomy were performed selectively, depending on the site of peritoneal metastasis. HIPEC was performed by circulating the mixed solution of 35 mg/m² of mitomycin-C and 3L of hypertonic solution (Dianeal, 1.5% Dextrose Peritoneal Dialysis Solution). Mitomycin-C was inserted 17.5 mg/m² initially and 8.8 mg/m² at 30 and 60 minutes. The mixed solution was circulated 800–1000 mL/min in a HIPEC pump (The Belmont Hyperthermic Pump) to maintain 42°C to 43°C for 90 minutes. The temperatures of both the inflow and outflow of the HIPEC solution, as well as the patient’s body temperature, were recorded every 5 minutes. Anastomosis of resected bowels was performed after HIPEC. A diverting ostomy was performed depending on the surgeon’s decision in consideration the risk of anastomotic leakage or the extent of CRS. All patients were sent to the ICU after surgery.
Table 1
Baseline characteristics of patients.

| Variables                          | N  |
|------------------------------------|----|
| Age, y                             | 56.1 ± 12.4 (24–76) |
| Sex                                |    |
| Male                               | 34 (51.5) |
| Female                             | 32 (48.5) |
| BMI, kg/m²                          | 23.3 ± 3.5 (16.6–32.0) |
| Combined morbidity                 | 27 (40.9) |
| ASA                                |    |
| 1                                  | 10 (15.2) |
| 2                                  | 33 (50.0) |
| 3                                  | 23 (34.8) |
| Primary cancer                     |    |
| Ascending colon cancer             | 18 (27.3) |
| Transverse colon cancer            | 5 (7.6) |
| Descending colon cancer            | 2 (3.0) |
| Sigmoid colon cancer               | 15 (22.7) |
| Rectosigmoid junction cancer       | 3 (4.5) |
| Rectal cancer                      | 10 (15.2) |
| Cecal cancer                       | 6 (9.1) |
| Appendiceal cancer                 | 7 (10.6) |
| Presentation of peritoneal metastasis |    |
| Synchronous                        | 24 (36.4) |
| Metachronous                       | 42 (63.6) |
| History of previous abdominal surgery|    |
| Yes                                | 50 (75.8) |
| No                                 | 16 (24.2) |
| Preoperative chemotherapy           |    |
| 1st line                           | 42 (63.6) |
| 2nd line                           | 25 (37.9) |
| 3rd line                           | 11 (16.7) |
| Synchronous organ metastasis       |    |
| Liver                              | 9 (13.6) |
| Lung                               | 1 (1.5) |
| Histology of primary colorectal cancer |    |
| Well-differentiated                | 3 (4.5) |
| Moderate-differentiated            | 41 (62.1) |
| Poor-differentiated                | 6 (9.1) |
| Mucinous                           | 14 (21.2) |
| Unknown and missing                | 2 (3.0) |
| Preoperative hemoglobin            | 12.3 ± 1.9 (7.0–16.8) |
| Preoperative albumin, g/dL         | 4.0 ± 0.5 (2.4–5.0) |
| Preoperative CRP                   | 23.4 ± 40.2 (0.2–189.1) |
| Preoperative CEA, ng/mL            | 30.9 ± 61.8 (0.3–338.0) |
| Peritoneal Surface Disease Severity Score (PSDSS) |    |
| Stage I                            | 0 (0.0) |
| Stage II                           | 38 (57.6) |
| Stage III                          | 6 (9.1) |
| Stage IV                           | 22 (33.3) |

ASA = American Society of Anesthesiologists, BMI = body mass index, CEA = carcinoembryonic antigen, CRP = C-reactive protein, PC = peritoneal carcinomatosis, PSDSS = Peritoneal Surface Disease Severity Score.

Assessment of PSDSS, 57.6% of the patients were stage II, which was a higher rate than the 9.1% of stage III and 33.3% of stage IV (Table 1).

3.2. Intraoperative outcomes

In assessment of extent of peritoneal carcinomatosis, the mean PCI was 15.3 ± 10.5 (range, 1–39), 33.3% of the patients had a PCI less than 10, 36.4% with a PCI of 10 to 19, and 30.3% greater than PCI 20. CC-0 was accomplished in 59.1% of the patients, and CC-1 was achieved in 18.2%. The mean operation time was 9.4 hours. Intraoperative transfusion was performed in 27.3% of the patients, and the mean amount of intraoperative blood loss was 563 mL. HIPEC was performed by the open method with the Coliseum technique, except in 1 case where the laparoscopic approach was used. Synchronous resection of the primary tumor during CRS plus HIPEC was performed in 24 patients (36.4%), whereas resection of the recurrent tumor was performed in 42 patients (63.6%). Among all patients, 20 patients additionally underwent combined operations to remove metastatic lesions of other organs during CRS. Total abdominal hysterectomy with bilateral oophorectomy was performed in 7.6% of the patients. In addition, liver metastasis was treated by surgical resection in 6 patients, and intraoperative radiofrequency ablation in 1 patient. Two other patients with synchronous liver metastasis were treated by systemic chemotherapy with targeted anticancer agents to induce resectable conversion of metastatic liver lesions. Bladder invasion from carcinomatosis was treated by cystectomy in 6.1% of the patients. Stoma formation was performed in 34.8% of the patients: colostomy (13.6%), ileostomy (18.2%), and jejunostomy (3.0%) (Table 2).

Table 2
Intraoperative outcomes.

| Variables                          | N  |
|------------------------------------|----|
| Peritoneal Cancer Index, PCI       |    |
| < 10                               | 22 (33.3) |
| 10–19                              | 24 (36.4) |
| ≥ 20                               | 20 (30.3) |
| Mean ± SD                          | 15.3 ± 10.5 |
| Completeness of cytoreduction (CC) |    |
| CC-0                               | 39 (60.1) |
| CC-1                               | 12 (18.2) |
| CC-2                               | 15 (22.7) |
| Operative time, h                  | 9.4 ± 3.1 (3.4–19.6) |
| Estimated blood loss, mL           | 565 (215–1337) |
| Intraoperative transfusion         |    |
| Yes                                | 18 (27.3) |
| No                                 | 48 (72.7) |
| Operative method                   |    |
| Open                               | 65 (98.5) |
| Laparoscopic                       | 1 (1.5) |
| Synchronous resection of primary tumor | 24 (36.4) |
| Rt. hemicolectomy                  | 12 (18.2) |
| Anterior resection                 | 7 (10.6) |
| Low anterior resection             | 3 (4.5) |
| Total colectomy                    | 2 (3.0) |
| Combined operations during CRS*    | 20 (30.3) |
| Cystectomy with ureteronecystectomy| 4 (6.1) |
| Segmental resection of ureter and ureterouterine cystectomy | 2 (3.0) |
| Liver resection (segmentectomy, or wedge resection) | 6 (9.1) |
| Intraoperative RFA                 | 1 (1.5) |
| TAH & BSO                          | 5 (7.6) |
| Splenectomy                        | 1 (1.5) |
| Excision of pancreatic mass        | 1 (1.5) |
| Stoma formation                    |    |
| None                               | 43 (65.2) |
| Colostomy                          | 9 (13.6) |
| Ileostomy                          | 12 (18.2) |
| Jejunostomy                        | 2 (3.0) |

*CC = completeness of cytoreduction, RFA = radiofrequency ablation, TAH & BSO = total abdominal hysterectomy & bilateral oophorectomy.

* Combined operations, except primary tumor resection and peritonectomy, were performed additionally to remove metastatic sites of other organs.

<ref>Table 1</ref>
### 3.3. Postoperative clinical outcomes

After surgery, the average lengths of stay in the ICU and the hospital were 1.7 days and 20.2 days, respectively. Levin tubes inserted before the operation were removed at 4.8 postoperative days. Closed suction drains were removed at 13.4 days on average. In addition, patients began to eat a soft diet at 9.5 postoperative days. Closed suction drains were removed at 13.4 postoperative days. In the ICU, patients were treated with adjuvant chemotherapy within the first 2 months. Targeted chemotherapeutic agents, such as bevacizumab or cetuximab, were used in 60.6% of the patients, and FOLFIRI with bevacizumab was used most commonly as the first line adjuvant chemotherapy after HIPEC. Re-admission related to postoperative complications occurred in 9.1% of the patients (Table 3).

### 3.4. Postoperative complications according to the clavien-dindo classification

The overall rate of short-term complications was 74.2%, whereas the rate of long-term complications was 10.6%. Among short-term complications, 62.1% were grade I-II complications, and 12.1% were grade III-V complications. Long-term complications consisted of grade III-V complications: grade III, 7.6%; grade IV, 1.5%; and grade V, 1.5%.

Among short-term complications, hematologic abnormalities were the most common grade II complications: neutropenia (15.2%) and thrombocytopenia (6.1%). In addition, 7.6% of the patients required transfusions postoperatively. Among patients with grade IIa complications, 3 received interventional therapies for pleural effusion, ureteral stricture, and postoperative bleeding. In addition, there were 4 patients who underwent a re-operation due to postoperative leak, intestinal obstruction, and wound evisceration as grade IIIb complications.

Among long-term complications, grade III complications were recorded in 5 patients (7.6%). In addition, 1 patient with a grade IV long-term complication suffered from septic shock, which developed from bile leakage after hepatectomy following CRS with HIPEC. The main cause of grade V complications was sepsis, which postoperatively occurred with pneumonia. Detailed descriptions are shown in Table 4, and the proportions of postoperative complications according to the follow-up period are demonstrated in Fig. 1.

### 4. Discussion

CRS and HIPEC have been applied to treat patients with peritoneal carcinomatosis originating from appendiceal cancer, colorectal cancer, ovarian cancer, and pseudomyxoma peritonei.

### Table 3: Postoperative clinical outcomes.

| Variables                          | N   |
|------------------------------------|-----|
| Length of ICU stay, day            | 1.7±1.4 (0–7) |
| Length of hospital stay, day       | 20.2±13.5 (8–70) |
| Days to extubation, day            | 0.6±0.9 (0–6) |
| Days to 1st sips of water, day     | 4.7±3.3 (1–21) |
| Days to 1st soft diet, day         | 9.5±6.8 (3–44) |
| Days to removal of Levin tube, day | 4.8±5.2 (0–29) |
| Days to removal of JP drain, day   | 13.4±8.0 (5–43) |
| Re-transfer to ICU after the operation |     |
| Sepsis                             | 2 (3.0) |
| Postoperative bleeding             | 1 (1.5) |
| Postoperative chemotherapy         |      |
| Yes                                | 51 (77.3) |
| No                                 | 15 (22.7) |

Regimen of 1st postoperative chemotherapy

| Bevacizumab + FOLFOX                | 10 (30.3) |
| Bevacizumab + FOLFIRI              | 2 (3.0) |
| Cetuximab + FOLFIRI                | 17 (25.8) |
| Cetuximab + Irinotecan             | 1 (1.5) |
| Capcitabine                        | 4 (6.1) |
| FOLFIRI                            | 1 (1.5) |
| FOLFOX                             | 6 (9.1) |

Interval of 1st postoperative chemotherapy, week

| Mean±SD | 8.0±9.3 (2–55) |
| Median, IQR | 5.0 (3–8) |
| Re-admission | 6 (9.1) |

ICU = intensive care unit, IQR = interquartile range, JP = Jackson-Pratt, SD = standard deviation.

### Table 4: Postoperative complications according to the Clavien-Dindo classification.

| Variables                          | N   |
|------------------------------------|-----|
| Short-term postoperative complications (< postoperative 30 days) |     |
| Grade I                            | 18 (27.3) |
| Fever                              | 7 |
| Abdominal pain                     | 2 |
| Constipation                       | 1 |
| Nausea/vomiting                    | 4 |
| Voiding difficulty                 | 2 |
| Wound seroma                       | 1 |
| High output of jejunostomy          | 1 |
| Grade II                           | 23 (34.8) |
| Intestinal obstruction             | 3 |
| Transfusion                        | 5 |
| Neutropenia                        | 10 |
| Thrombocytopenia                   | 4 |
| Tachycardia                        | 1 |
| Grade IIIa                         | 3 (4.5) |
| Pleural effusion                   | 1 |
| Ureteral stricture                 | 1 |
| Postoperative bleeding             | 1 |
| Grade IIIb                         | 4 (6.1) |
| Anastomotic leakage                | 1 |
| Urinary leakage from bladder       | 1 |
| Intestinal obstruction             | 1 |
| Wound evisceration                 | 1 |
| Grade IV                           | 1 (1.5) |
| Postoperative bleeding             | 0 (0.0) |
| Long-term postoperative complications (> postoperative 30 days) |     |
| Grade I                            |       |
| Grade II                           |       |
| Grade IIIa                         |       |
| Grade IIIb                         | 5 (7.6) |
| Intestinal obstruction             | 3 |
| Perforation of small bowel         | 1 |
| Ureteral stricture                 | 1 |
| Grade IV                           |       |
| Septic shock                       | 1 (1.5) |
| Grade V                            | 1 (1.5) |

FOLFOX 6 (9.1) | Capcitabine 4 (6.1) | Cetuximab + Irinotecan 1 (1.5) | Bevacizumab + FOLFOX 20 (30.3) | Bevacizumab + FOLFIRI 2 (3.0) | Cetuximab + FOLFIRI 17 (25.8) | Cetuximab + Irinotecan 1 (1.5) | Capcitabine 4 (6.1) | FOLFIRI 1 (1.5) | FOLFOX 6 (9.1)
et al. reported that the median operation time was 430 minutes and a hospital stay of 22 days. In addition, Polanco underwent CRS with HIPEC showed a mean operation time of this study, we used 35mg/m² of mitomycin-C mixed in 3L of crucial to select proper anticancer drugs directed for HIPEC. In this study, we used 35 mg/m² of mitomycin-C mixed in 3L of 1.5% dextrose peritoneal dialysis solution, which was a similar protocol of Verwaal et al. However, mitomycin-C has adverse effects of myelosuppression and renal toxicity. Predisposing factors that decrease excretion of mitomycin-C from the kidney and increase plasma concentration of mitomycin-C might affect postoperative myelosuppression after HIPEC. In addition, immunologic suppression from postoperative surgical stress might aggravate its negative impact on postoperative recovery in hematopoietic systems. Thus, it is important to conduct proper patient selection and to consider dose reductions of anticancer agents for HIPEC in patients who have a very low BMI, long period of prior chemotherapies, decreased renal function, and are older than 60 years old.

Postoperative complications occurred in 74.2% of the patients in the short-term period and in 10.6% in the long-term period. In the short-term period, grade I-II complications developed in 62.1% of the patients. The most common complications of grade II were hematologic abnormalities: neutropenia (15.2%) and thrombocytopenia (6.1%). These developed within 5–7 postoperative days and were treated using hematopoietic agents. In previous studies, the rates of postoperative major complications after CRS with HIPEC were approximately 30–40%. However, the rate of postoperative major complications in this study was 12.1% in the short-term period and 10.6% in the long-term period. Although CRS and HIPEC were performed in just 66 cases as an early experience, our results for postoperative complications are acceptable, compared to previous reports. On the other hand, while the majority of short-term complications were grades I-II, all long-term complications were grades III-V as shown in Fig. 1. This suggests that long-term complications require more attention, because they can result in more severe morbidities, compared to short-term complications. It is known that CRS with HIPEC requires a steep learning curve (100–140 cases) to ensure proficient performance of the techniques. Because of the aggressive and high-skilled procedures of CRS with HIPEC, postoperative morbidities have been found to differ among institutions, from 10% to 60%. However, it is remarkable that the rate of perioperative mortality is nearly zero at high-volume centers with greater experience with CRS with HIPEC. In these aspects, intensive training and sustained efforts to accumulate surgical experience are key to achieving successful postoperative outcomes after CRS with HIPEC.

Both PCI and CC scores are regarded as key prognostic factors that affect the clinical and oncologic outcomes after CRS with HIPEC. Because PCI assesses tumor distribution quantitatively, it can predict the likelihood of complete cytoreduction. As shown in Fig. 2, patients with low PCI had high rates of CC-0. On the other hand, patients with high PCI had low rates of CC-0 and high rates of CC-2. These correlations suggest that extensive peritoneal seeding can result in incomplete resections and a poor prognosis. In this study, CC-2 occurred in 22.7% of the patients. Although preoperative imaging studies were performed to examine the extent of peritoneal carcinomatosis before CRS with HIPEC, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative manipulation of the primary cancer and cancer-contaminated fluid can result in local-regional dissemination of tumor cells. In addition, spillage of free cancer cells in the abdominal cavity can be implanted in the peritoneal surface and progress to peritoneal metastasis. In addressing these issues, HIPEC has advantages of eradicating residual tumor cells in the peritoneal space, allowing anticancer agents to penetrate into the tumor core and increase cytotoxic effects. Since Sugarbaker et al. in 1985, CRS with HIPEC has been regarded as an effective treatment to prolong survival in patients with colorectal cancer with peritoneal carcinomatosis. According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative manipulation of the primary cancer and cancer-contaminated fluid can result in local-regional dissemination of tumor cells. In addition, spillage of free cancer cells in the abdominal cavity can be implanted in the peritoneal surface and progress to peritoneal metastasis. In addressing these issues, HIPEC has advantages of eradicating residual tumor cells in the peritoneal space, allowing anticancer agents to penetrate into the tumor core and increase cytotoxic effects. Since Sugarbaker et al. in 1985, CRS with HIPEC has been regarded as an effective treatment to prolong survival in patients with colorectal cancer with peritoneal carcinomatosis.

According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative manipulation of the primary cancer and cancer-contaminated fluid can result in local-regional dissemination of tumor cells. In addition, spillage of free cancer cells in the abdominal cavity can be implanted in the peritoneal surface and progress to peritoneal metastasis. In addressing these issues, HIPEC has advantages of eradicating residual tumor cells in the peritoneal space, allowing anticancer agents to penetrate into the tumor core and increase cytotoxic effects. Since Sugarbaker et al. in 1985, CRS with HIPEC has been regarded as an effective treatment to prolong survival in patients with colorectal cancer with peritoneal carcinomatosis.

According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find

According to the tumor cell entrapment hypothesis, intraoperative PCI was usually higher than preoperatively predicted values, because it is still difficult to find
small peritoneal seeding nodules in the current CT scans. Preoperatively, improved diagnosis of the extent of peritoneal seeding is necessary to determine a patient’s eligibility for CRS with HIPEC and to enhance both postoperative and oncologic outcomes.

This study has limitations of using a small study population to assess short-term outcomes after CRS plus HIPEC. Although our prospective data collection offers advantages of recording detailed postoperative outcomes, assessment with larger numbers of patients is needed to confirm our clinical outcomes after CRS with HIPEC. However, this study is still meaningful as we demonstrated acceptable short-term clinical outcomes of CRS with HIPEC, which can be used as effective treatment strategies to treat peritoneal metastasis from colorectal cancer.

In conclusion, CRS with HIPEC was deemed feasible for treating appendiceal and colorectal cancer with peritoneal metastasis. We expect that this method will be more widely accepted in treating peritoneal carcinomatosis in patients with stage IV appendiceal and colorectal cancer.

Acknowledgments

The authors thank MiSun Park for the English language editing of this manuscript and Dong-So Jang, MFA, (Medical Illustrator, Seoul, Korea) for his help with the illustrations.

References

[1] Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92.
[2] Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum 1991;34:723–7.
[3] Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg 1999;384:576–87.
[4] Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastroenterol 2010;2:19–30.
[5] Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43.
[6] Verwaal VJ, Brunn S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–32.
[7] Elias D, Gilly F, Bontine F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63–8.
[8] Canda AE, Sökmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1082–7.
[9] Kuipers AM, Hauptmann M, Aalbers AG, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reasserted. Eur J Surg Oncol 2016;42:244–50.
[10] Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intra-abdominal chemotherapy in peritoneal surface malignancies. Ann Surg 2012;255:348–56.
[11] Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009;249:900–7.
[12] Kusamura S, Baratti D, Virzi S, et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol 2013;107:312–9.
[13] Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:1330–6.
[14] Pelz JO, Stoijadinovic A, Nussan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009;99:9–15.
[15] Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187–96.
[16] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new system of classification of surgical complications: a new system. Ann Surg 2004;240:205–13.
[17] Sugarbaker PH. Peritoneectomy procedures. Ann Surg 1995;221:29–42.
[18] Sugarbaker PH. Management of peritoneal metastases—basic concepts. J BUON 2015;20(suppl 1):S2–11.
[19] Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 2016;48:42–9.
[20] Elias D, Lefrere JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681–5.
[21] Sugarbaker PH, Giano LA, Spyker JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985;98:414–22.
[22] Polanco PM, Ding Y, Knox JM, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol 2015;22:1673–9.
[23] Cho MS, Kim CW, Baek SJ, et al. Minimally invasive versus open total mesorectal excision for rectal cancer: long-term results from a case-matched study of 633 patients. Surgery 2015;157:1121–9.
[24] Park EJ, Cho MS, Baek SJ, et al. Long-term oncologic outcomes of robotic low anterior resection for rectal cancer: a comparative study with laparoscopic surgery. Ann Surg 2015;261:129–17.
[25] Yan TD, Cao CQ. Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol 2010;2:109–16.
[26] Baratti D, Kusamura S, Iusco D, et al. Perioperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum 2014;57:658–68.
[27] Moradi BN, 3rd, Esquivel J. Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2009;100:293–6.
[28] Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15:734–63.
[29] Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf) 2006;28:373–8.
[30] Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 2012;13:e362–9.